I am a
Home I AM A Search Login

Papers of the Week

Papers: 1 Jan 2022 - 7 Jan 2022

Human Studies, Pharmacology/Drug Development

2022 Jan 06

Rheumatol Ther

Maintenance of Patient-Reported Outcomes in Baricitinib-Treated Patients with Moderate-to-Severe Active Rheumatoid Arthritis: Post Hoc Analyses from Two Phase 3 Trials.


Sholter D, Wu J, Jia B, Zhang H, Griffing K, Birt J, Reis P J S, Liu H, Bingham CO
Rheumatol Ther. 2022 Jan 06.
PMID: 34990002.


Baricitinib has been shown to improve patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA) who are inadequate responders (IR) to conventional synthetic and biologic disease-modifying antirheumatic drugs (csDMARDs and bDMARDs, respectively). We assessed the ability of baricitinib 2-mg to maintain minimal clinically important differences (MCIDs) in PROs until week 24 among week 4 and 12 responders.